A hearing in the German Bundestag has triggered fresh controversy over the approval and safety of COVID-19 mRNA ‘vaccines’, after a former chief Pfizer toxicologist confirmed that critical safety testing was bypassed during development.
Speaking at the Corona Investigation session on March 19, 2026, Dr Helmut Sterz said “essential toxicity studies were sacrificed to speed, without acceptable reasons,” adding that the vaccine’s approval effectively resulted in “prohibited human trials.”
The claims were presented during a session organised by an opposition-led committee, with reports indicating the testimony was limited to a brief five-minute window.
Dr Helmut Sterz, former Chief Toxicologist of Pfizer Europe, speaking at the Corona Investigation in the Bundestag, March 19, 2026.
“Essential toxicity studies were sacrificed to speed, without acceptable reasons..
The approval led to prohibited human trials” pic.twitter.com/0XHSLYc06C— RefugeOfSinners (ROS) (@RefugeOfSinner5) March 22, 2026
The hearing has since been highlighted by international medical figures, including cardiologist Dr Aseem Malhotra and eminent Indian cardiologist Prof. Deepak Natarajan, who said the session raised serious concerns that had largely gone unnoticed amid global focus on escalating Middle East tensions.
One of India’s most eminent cardiologist’s, referencing Pfizer’s former Chief Toxicologist alludes to the fact that the Covid mRNA jabs may be behind a surge in cancer. Thank you for speaking out Deepak 🙏 https://t.co/Ww4AYfa4An
— Dr Aseem Malhotra (@DrAseemMalhotra) March 23, 2026
Dr Natarajan stated the committee was told the Pfizer mRNA COVID-19 vaccine “should have never been approved for use by the public,” alleging it was inadequately tested for birth-related risks and carcinogenicity. The COVID mRNA ‘vaccine’ also did not prevent severe COVID-19 and instead increased age-adjusted mortality.
The shocking testimony suggest that key safety protocols—particularly around long-term toxicity, cancer risk, and reproductive effects—were not fully completed prior to public rollout, with mass populations exposed to a pharmaceutical product without the full spectrum of standard toxicological validation. The approval process shifted experimental risk directly onto the public rather than within controlled clinical frameworks.
Experts agreed that the testimony presented a fundamental challenge to the safety profile of the COVID-19 mRNA ‘vaccines’ and should have far-reaching consequences for regulatory oversight, pharmaceutical accountability, and public health policy.
The limited time allocated to the Bundestag hearing, alongside the lack of broader coverage in the legacy media, has also been raised by commentators as a factor in the muted global response to the allegations.
